Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine With or Without Bortezomib in Older Patients With AML
NCT01420926Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2011
- Primary completion
- Jun 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Nov 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01420926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01420926.